Failure of liver transplantation to diminish cardiac deposits of amylopectin and leukocyte inclusions in type iv glycogen storage disease
Philip Rosenthal, Luis Podesta, Robert Grier, Jonathan W. Said, Linda Sher, Jose Cocjin, Frederick Watanabe, Eric Vasiliauskas, Robert Van De Velde, Leonard Makowka – 1 November 1995 – Orthotopic liver transplantation has been used to treat glycogen storage disease type IV. Most long‐term surviving patients who have undergone liver transplantation have been free of neuromuscular and cardiac morbidity, and regression of cardiac amylopectin infiltration has been reported after liver transplantation. Leukocyte inclusions in glycogen storage disease type IV have also been reported.